PMID- 17144987
OWN - NLM
STAT- MEDLINE
DCOM- 20070501
LR  - 20161124
IS  - 0300-8932 (Print)
IS  - 0300-8932 (Linking)
VI  - 59
IP  - 11
DP  - 2006 Nov
TI  - [Clinical and echocardiographic follow-up of patients with hypertrophic 
      obstructive cardiomyopathy treated by percutaneous septal ablation].
PG  - 1123-30
AB  - INTRODUCTION AND OBJECTIVES: Alcohol septal ablation is a therapeutic option for 
      patients with hypertrophic obstructive cardiomyopathy who remain symptomatic 
      despite medical treatment. Our aim was to monitor clinical and echocardiographic 
      progression in patients with hypertrophic obstructive cardiomyopathy treated by 
      septal ablation at our center. METHODS: Thirty-five septal ablations were 
      performed in 34 patients (79% male) who had symptomatic hypertrophic obstructive 
      cardiomyopathy despite optimum medical treatment. The procedure was successful in 
      32 (i.e., the reduction in left ventricular outflow tract pressure gradient, or 
      LVOTPG, was >50%). During clinical and echocardiographic follow-up, New York 
      Heart Association (NYHA) functional class and LVOTPG were monitored. RESULTS: The 
      patients' mean age was 63 (12) years. The mean follow-up period was 9 (3) months. 
      Immediately after septal ablation, LVOTPG decreased significantly, from 74.2 
      (25.3) mm Hg to 26 (25) mm Hg (P<.001), and remained low throughout follow-up. 
      Moreover, echocardiography showed that the interventricular septum thickness also 
      decreased during follow-up, from 19 (3) mm to 15 (2) mm (P<.0001). A significant 
      improvement in NYHA functional class (from 93% in class III-IV to 84% in class 
      I-II) was also observed. Two deaths occurred within 48 hours after the procedure. 
      The most frequent complication was complete heart block (20%; n=6). CONCLUSIONS: 
      Alcohol septal ablation is effective in patients with hypertrophic obstructive 
      cardiomyopathy who remain symptomatic despite medical treatment. However, the 
      procedure is associated with a significant rate of complications and should, 
      therefore, be reserved for selected patients, in particular for elderly patients 
      and those with comorbid conditions.
FAU - Delgado, Victoria
AU  - Delgado V
AD  - Institut Clinic del Torax, Hospital Clinic, IDIBAPS (Institut d'Investigacions 
      Biomediques August Pi i Sunyer), Facultad de Medicina, Universidad de Barcelona, 
      Barcelona, Spain.
FAU - Sitges, Marta
AU  - Sitges M
FAU - Andrea, Rut
AU  - Andrea R
FAU - Rivera, Socorro
AU  - Rivera S
FAU - Masotti, Monica
AU  - Masotti M
FAU - Francino, Antonio
AU  - Francino A
FAU - Azqueta, Manuel
AU  - Azqueta M
FAU - Pare, Carles
AU  - Pare C
FAU - Betriu, Amadeo
AU  - Betriu A
LA  - spa
PT  - Journal Article
TT  - Seguimiento clinico y ecocardiografico de pacientes con miocardiopatia 
      hipertrofica obstructiva tratados con ablacion septal percutanea.
PL  - Spain
TA  - Rev Esp Cardiol
JT  - Revista espanola de cardiologia
JID - 0404277
RN  - 3K9958V90M (Ethanol)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Cardiomyopathy, Hypertrophic/*diagnostic imaging/*therapy
MH  - *Catheterization
MH  - Ethanol/*administration & dosage
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Ultrasonography
EDAT- 2006/12/06 09:00
MHDA- 2007/05/02 09:00
CRDT- 2006/12/06 09:00
PHST- 2006/12/06 09:00 [pubmed]
PHST- 2007/05/02 09:00 [medline]
PHST- 2006/12/06 09:00 [entrez]
AID - 13095781 [pii]
PST - ppublish
SO  - Rev Esp Cardiol. 2006 Nov;59(11):1123-30.